ARTICLE | Emerging Company Profile
IgGenix: antibody engineering for food allergies
IgGenix is blocking the inflammatory response in food allergies with redesigned antibodies
November 7, 2020 2:46 AM UTC
IgGenix is pairing single-cell sequencing with antibody engineering to create a new class of food allergy therapies that selectively suppresses allergen-triggered immunity while sidestepping the risky steps of desensitizing immunotherapy.
The company launched in August with a $10 million series A round it plans to use to de-risk the platform, build a pipeline of food allergy therapies and bring on a new CEO. Khosla Ventures led the round; Parker Ventures also participated...